PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers

LAGUNA HILLS, Calif., Dec. 27, 2016, PMCB, (GLOBE NEWSWIRE) PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that recent research performed at the Ann and Robert H. Lurie Children s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine and published in the journal Child’s Nervous System provides further support for PharmaCyte’s efforts to develop a targeted cannabinoid-based chemotherapy for
http://bit.ly/2iAXe65